ECSP22067275A - Anticuerpos anti-cd19 humano - Google Patents

Anticuerpos anti-cd19 humano

Info

Publication number
ECSP22067275A
ECSP22067275A ECSENADI202267275A ECDI202267275A ECSP22067275A EC SP22067275 A ECSP22067275 A EC SP22067275A EC SENADI202267275 A ECSENADI202267275 A EC SENADI202267275A EC DI202267275 A ECDI202267275 A EC DI202267275A EC SP22067275 A ECSP22067275 A EC SP22067275A
Authority
EC
Ecuador
Prior art keywords
antibodies
human
human anti
bind
compositions
Prior art date
Application number
ECSENADI202267275A
Other languages
English (en)
Inventor
Jeffrey Streetman Boyles
Alison Lee Sim Budelsky
Guifeng Zhang
Songqing Na
Barrett Allan
Kira Vladimirovna Rubtsova
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP22067275A publication Critical patent/ECSP22067275A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a anticuerpos que se unen a CD19 humano ("anticuerpos anti-CD19 humano" o "anticuerpos anti-CD19 humano"), composiciones que comprenden dichos anticuerpos anti-CD19 humano y métodos para usar dichos anticuerpos anti-CD19 humano.
ECSENADI202267275A 2020-02-28 2022-08-26 Anticuerpos anti-cd19 humano ECSP22067275A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062983093P 2020-02-28 2020-02-28

Publications (1)

Publication Number Publication Date
ECSP22067275A true ECSP22067275A (es) 2022-09-30

Family

ID=74885029

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202267275A ECSP22067275A (es) 2020-02-28 2022-08-26 Anticuerpos anti-cd19 humano

Country Status (20)

Country Link
US (1) US11623956B2 (es)
EP (1) EP4110815A1 (es)
JP (1) JP7450743B2 (es)
KR (1) KR20220132579A (es)
CN (1) CN115151570A (es)
AR (1) AR121370A1 (es)
AU (1) AU2021225792A1 (es)
BR (1) BR112022015902A2 (es)
CA (1) CA3169155A1 (es)
CL (1) CL2022002329A1 (es)
CO (1) CO2022012212A2 (es)
CR (1) CR20220421A (es)
DO (1) DOP2022000173A (es)
EC (1) ECSP22067275A (es)
IL (1) IL295494A (es)
JO (1) JOP20220204A1 (es)
MX (1) MX2022010621A (es)
PE (1) PE20221593A1 (es)
TW (1) TWI790548B (es)
WO (1) WO2021173471A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202346576A (zh) 2022-04-13 2023-12-01 新加坡商泰莎治療有限公司 治療性t細胞產品
TW202346359A (zh) 2022-04-15 2023-12-01 美商凱維那醫療公司 用於治療自體免疫疾病之方法及組合物
WO2023240064A1 (en) 2022-06-08 2023-12-14 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1966245E (pt) 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
PL2066349T3 (pl) * 2006-09-08 2012-09-28 Medimmune Llc Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
WO2015171863A1 (en) 2014-05-08 2015-11-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. USING B-CELL-TARGETING ANTIGEN IgG FUSION AS TOLEROGENIC PROTEIN THERAPY FOR TREATING ADVERSE IMMUNE RESPONSES
ES2963807T3 (es) 2016-06-08 2024-04-02 Xencor Inc Tratamiento de enfermedades relacionadas con la IgG4 con anticuerpos anti-CD19 de reticulación a CD32B

Also Published As

Publication number Publication date
EP4110815A1 (en) 2023-01-04
CR20220421A (es) 2022-09-23
IL295494A (en) 2022-10-01
CN115151570A (zh) 2022-10-04
JP7450743B2 (ja) 2024-03-15
JOP20220204A1 (ar) 2023-01-30
AR121370A1 (es) 2022-06-01
DOP2022000173A (es) 2022-10-31
MX2022010621A (es) 2022-11-30
CL2022002329A1 (es) 2023-04-10
CO2022012212A2 (es) 2022-09-09
KR20220132579A (ko) 2022-09-30
US20210269520A1 (en) 2021-09-02
JP2023515219A (ja) 2023-04-12
CA3169155A1 (en) 2021-09-02
WO2021173471A1 (en) 2021-09-02
BR112022015902A2 (pt) 2022-10-04
PE20221593A1 (es) 2022-10-10
US11623956B2 (en) 2023-04-11
AU2021225792A1 (en) 2022-09-15
TWI790548B (zh) 2023-01-21
TW202146451A (zh) 2021-12-16

Similar Documents

Publication Publication Date Title
CO2022012212A2 (es) Anticuerpos anti-cd19 humano
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
AR114541A1 (es) Constructos de anticuerpos para cldn18.2 y cd3
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
BR112018067458A2 (pt) anticorpos para tigit
CL2021003535A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional de solicitud 3095-2019)
UY39135A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
CL2021000089A1 (es) Anticuerpos anti -sortilina y métodos para su uso.
CL2021000258A1 (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
CL2021000849A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999)
CL2022001673A1 (es) Anticuerpos contra la integrina alfa 11 beta 1.
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
CL2020002680A1 (es) Anticuerpos para radionúclidos quelados
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
CO2023008643A2 (es) Anticuerpos anti-hla-g y uso de estos
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
AR122674A1 (es) Anticuerpos de unión a cd3 y cd19
PE20240725A1 (es) Anticuerpos anti-nectina-4 y usos de los mismos
CL2023000701A1 (es) Anticuerpos que se unen a il1rap y usos de los mismos
CL2023001052A1 (es) Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
CO2023015915A2 (es) Anticuerpos anti-ccr8
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения